What is VTE?
Venous thromboembolism (VTE) is a collective term that encompasses two related conditions: deep vein thrombosis (DVT), which is a blood clot that forms in the deep veins (typically in the legs), and pulmonary embolism (PE), which occurs when a clot breaks off and travels to the lungs. 1, 2
Clinical Significance
VTE represents a major cause of cardiovascular morbidity and mortality:
- Third leading cause of cardiovascular death worldwide, after myocardial infarction and stroke 3
- Accounts for 5-10% of all in-hospital deaths directly from PE 1
- Incidence of approximately 1 case per 1,000 persons per year in the United States 1
- Results in 200,000-300,000 hospitalizations annually 1
Pathophysiology
VTE develops through a combination of:
- Blood stasis
- Plasma hypercoagulability
- Endothelial dysfunction
The process typically starts in the valve pockets of large veins and involves leukocytes, platelets, tissue factor-positive microvesicles, and various coagulation factors 3.
Clinical Consequences
Acute Complications
- 26% of patients with undiagnosed/untreated PE will have a subsequent fatal embolic event 1
- Another 26% will experience nonfatal recurrent embolic events 1
- Immediate risks include chest pain, shortness of breath, and death 4
Long-term Complications
- Postthrombotic syndrome - causes lifelong limb pain and edema 2, 4
- Post-PE syndrome and chronic thromboembolic pulmonary hypertension 5
- Recurrence rate of approximately 20% after 5 years 2
- Significant adverse impact on quality of life 5
Risk Factors
Both genetic and acquired factors contribute to VTE risk 3:
- Non-O blood groups
- Factor V Leiden mutation
- Oral contraceptive use and hormone replacement therapy
- Advanced age
- Surgery and hospitalization
- Long-haul travel
- Cancer
Most hospitalized medical patients have at least one risk factor for VTE, and this risk persists for several weeks after discharge 1.